Yasuhito Suehara

Yasuhito Suehara

Auto-generated profile, based on publicly available information

Yasuhito Suehara

Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2017 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
JHJ Hillengass
J Hillengass
LMLia Angela Moulopoulos
Lia Angela Moulopoulos
Stefan DelormeStefan Delorme
Stefan Delorme
VKVassilis Koutoulidis
Vassilis Koutoulidis
JMJ Mosebach
J Mosebach
ETE Terpos
E Terpos
For decades, conventional skeletal survey (CSS) has been the standard imaging technique for multiple myeloma (MM). However, recently whole-body computed tomography (WBCT) has been implemented into the diagnostic criteria of MM. This analysis compares sensitivity and prognostic significance of WBCT and CSS in patients with smoldering MM (SMM) and MM. Fifty-four of 212 patients (25.5%) had a negative CSS and a positive WBCT for osteolytic lesions (P<0.0001). Of 66 patients with SMM based on CSS, 12 (22.2%) had osteolytic lesions on WBCT. In comparison, WBCT failed to detect some bone destructions in the appendicular skeleton possibly due to limitations of the field of view. Presence of lytic bone lesions in WBCT was of borderline prognostic significance (P=0.051) for SMM patients, with a median time to progression of 38 versus 82 months for those without bone destructions. In conclusion, WBCT identifies significantly more sites of bone destruction than CSS. More than 20% of patients with SMM according to CSS have in fact active MM detectable with WBCT. On the basis of this and other studies, WBCT (either computed tomography (CT) alone or as part of a positron emission tomography-CT protocol) should be considered the current standard for the detection of osteolytic lesions in MM.

19 November 2017 in Cancer Science
Verified
Journal Article
Open access
PDF file
KHKeiichiro Hattori
Keiichiro Hattori
MSMamiko Sakata‐Yanagimoto
Mamiko Sakata‐Yanagimoto
YSYasuhito Suehara
Yasuhito Suehara
YYYasuhisa Yokoyama
Yasuhisa Yokoyama
TKTakayasu Kato
Takayasu Kato
SCShigeru Chiba
Shigeru Chiba
Recent sequencing studies demonstrated the MYD88 L265P mutation in more than 70% of primary central nervous system lymphomas (PCNSL), and the clinical significance of this mutation has been proposed as diagnostic and prognostic markers in PCNSL. In contrast, mutational analyses using cell‐free DNAs have been reported in a variety of systemic lymphomas. To investigate how sensitively the MYD88 L265P mutation can be identified in cell‐free DNA from PCNSL patients, we carried out droplet digital PCR (ddPCR) and targeted deep sequencing (TDS) in 14 consecutive PCNSL patients from whom paired tumor‐derived DNA and cell‐free DNA was available at diagnosis. The MYD88 L265P mutation was found in tumor‐derived DNA from all 14 patients (14/14, 100%). In contrast, among 14 cell‐free DNAs evaluated by ddPCR (14/14) and TDS (13/14), the MYD88 L265P mutation was detected in eight out of 14 (ddPCR) and in 0 out of 13 (TDS) samples, implying dependence on the detection method. After chemotherapy, the MYD88 L265P mutation in cell‐free DNAs was traced in five patients; unexpectedly, the mutations disappeared after chemotherapy was given, and they remained undetectable in all patients. These observations suggest that ddPCR can sensitively detect the MYD88 L265P mutation in cell‐free DNA and could be used as non‐invasive diagnostics, but may not be applicable for monitoring minimal residual diseases in PCNSL.

22 February 2018 in Haematologica
Verified
Journal Article
Closed access
PDF file
YSYasuhito Suehara
Yasuhito Suehara
MSMamiko Sakata-Yanagimoto
Mamiko Sakata-Yanagimoto
KHKeiichiro Hattori
Keiichiro Hattori
TNToru Nanmoku
Toru Nanmoku
TITakayoshi Itoh
Takayoshi Itoh
SCShigeru Chiba
Shigeru Chiba

31 July 2015 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
YNY Nishida
Y Nishida
YMYuya Matsue
Yuya Matsue
YSY Suehara
Y Suehara
KFK Fukumoto
K Fukumoto
MFM Fujisawa
M Fujisawa
KMK Matsue
K Matsue
Clinical significance of medullary abnormalities in the appendicular skeleton (AS) detected by low-dose whole-body multidetector computed tomography (MDCT) in patients with multiple myeloma (MM) was investigated. A total of 172 patients with monoclonal gammopathy of undetermined significance (MGUS) (n=17), smoldering MM (n=47) and symptomatic MM (n=108) underwent low-dose MDCT. CT values (CTv) of medullary density of AS⩾0 Hounsfield unit (HU) was considered as abnormal. Percentage of medullary abnormalities and the mean CTv of AS in patients with MGUS, smoldering MM and symptomatic MM were 18, 55 and 62% and −44.5 , −20.3 and 11.2 HU, respectively (P<0.001 and P<0.001). Disease progression of MM was independently associated with high CTv on multivariate analysis. In symptomatic MM, the presence of abnormal medullary lesions was associated with increased incidence of high-risk cytogenetic abnormalities (34.4% vs 7.7%; P=0.002) and extramedullary disease (10.4% vs 0%; P=0.032). It was also an independent poor prognostic predictor (hazard ratio 3.546, P=0.04). This study showed that CTv of AS by MDCT is correlated with disease progression of MM, and the presence of abnormal medullary lesions is a predictor for poor survival.

3 May 2016 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
KMKosei Matsue
Kosei Matsue
YMYuya Matsue
Yuya Matsue
KKKaoru Kumata
Kaoru Kumata
YUYoshiaki Usui
Yoshiaki Usui
YSYasuhito Suehara
Yasuhito Suehara
MTMasami Takeuchi
Masami Takeuchi

9 October 2014 in Cancer Science
Verified
Journal Article
Open access
PDF file
MFManabu Fujisawa
Manabu Fujisawa
KSKeisuke Seike
Keisuke Seike
KFKouta Fukumoto
Kouta Fukumoto
YSYasuhito Suehara
Yasuhito Suehara
MFMasafumi Fukaya
Masafumi Fukaya
KMKosei Matsue
Kosei Matsue
The emergence of oligoclonal bands (OB) has been reported in patients with multiple myeloma (MM) after stem cell transplantation (SCT) or successful chemotherapy. However, their clinical relevance remains unclear. We reviewed the clinical records of MM patients from January 2006 to May 2014. Treatment response was evaluated by International Working Group (IMWG) criteria. Serum immunofixation tests were performed at least every 3 months if the patient achieved more than very good partial response (VGPR). Free light chain (FLC) and minimal residual disease measurement by multicolor flow cytometry (MFC) were performed to evaluate the response to treatment. Among the 163 patients included in the study, 40 developed OB. Detection rates of OB in patients with complete response (CR), VGPR and partial response (PR) or less were 51.8, 36.3 and 0%, respectively. Patients with OB showed better progression‐free survival (PFS) and overall survival (OS) rates than those without OB (P = 0.028 and P < 0.001, respectively). However, if the patients were limited to ≥VGPR or CR, development of OB did not affect PFS (P = 0.621 and P = 0.646, respectively) or OS (P = 0.189 and P = 0.766, respectively). OB was observed in 60% of patients after SCT, and in 36.6% of patients with more than VGPR without SCT (P < 0.001). Patients with OB tended to have less minimal residual disease than those without OB (P = 0.054) and its presence may affect the stringent CR criteria. In conclusion, the emergence of OB was seen exclusively in patients with favorable responses, but its emergence per se could not be translated to improved survival.